<DOC>
<DOCNO>1050924_business_story_5278302.utf8</DOCNO>
<TEXT>


The Telegraph - Calcutta : Business

 Matrix in joint venture with Aspen

 OUR SPECIAL CORRESPONDENT

 Mumbai, Sept. 23: The Hyderabad-based Matrix Laboratories has signed a joint venture agreement with Aspen Pharmacare Holdings Ltd of South Africa to cater to the treatment of HIV/AIDS.

 According to the agreement, Matrix will transfer one of its active pharmaceutical ingredients (APIs) manufacturing facility to an Indian joint venture company, Astrix Laboratories Ltd, for a consideration of $36 million. Aspen and Matrix will each own 50 per cent in Astrix. 

 The amount of $36 million is expected to be received by the company on January 1, which is the closing date of the transaction. 

 On the other hand, Aspen Pharmacare will pick up a 50 per cent stake in Astrix for a consideration of $36.5 million.

 According to Matrix, Astrix will be the lead supplier of anti-retroviral APIs to Aspen. 

 Matrix will also pick up a 50 per cent stake in Fine Chemical Corporation (FCC), South Africa, for a consideration of $20 million, which will be paid on January 1. 

 FCC, which is currently 100 per cent owned by Aspen, has a US FDA approved API manufacturing facility in Cape Town.




</TEXT>
</DOC>